Financial Performance Forecast - The company expects a net profit attributable to shareholders of between 36 million and 46 million yuan for 2024, an increase of 23.03 million to 33.03 million yuan compared to the previous year, representing a year-on-year increase of 177.56% to 254.66%[2] - The expected net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between 28 million and 38 million yuan, reflecting a year-on-year increase of 160.95% to 254.15%[3] - The net profit for the same period last year was 12.97 million yuan, with a net profit of 10.73 million yuan after deducting non-recurring gains and losses[4] - The earnings per share for the previous year was 0.0342 yuan[5] - The performance forecast period is from January 1, 2024, to December 31, 2024[3] - The forecast data has not been audited by registered accountants[3] - There are no significant uncertainties affecting the accuracy of this performance forecast[7] Business Operations and Strategies - The company has enhanced market promotion, improved technical capabilities, and increased R&D efficiency, contributing to significant profit growth[6] - Non-operating gains during the reporting period were primarily from bank wealth management income and the write-off of uncollectible receivables[6] Investment Risks - Investors are advised to pay attention to investment risks as the forecast data is preliminary and subject to change in the official annual report[8]
百花医药(600721) - 2024 Q4 - 年度业绩预告